SOURCE: CymaBay Therapeutics

CymaBay Therapeutics Logo

May 29, 2015 08:00 ET

CymaBay to Present at the Jefferies 2015 Global Healthcare Conference

NEWARK, CA--(Marketwired - May 29, 2015) - CymaBay Therapeutics Inc. (NASDAQ: CBAY) announced today that senior management will present a corporate update at the Jefferies 2015 Global Healthcare Conference on Thursday, June 4, at 10:00 a.m. ET at the Grand Hyatt in New York City.

The presentation will be webcast live and available for replay for up to 30 days at http://ir.cymabay.com/events.

About CymaBay

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate, CymaBay's lead product candidate, has shown two therapeutic actions in a single drug in multiple Phase 2 gout studies. In gout patients, arhalofenate is intended to prevent painful flares in joints while at the same time promoting excretion of uric acid by the kidney, thereby addressing both the signs and symptoms of gout and the hyperuricemia that is the root cause of the disease. CymaBay's second product candidate, MBX-8025 is a potent, selective, orally active PPARδ agonist. A Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has initiated a pilot study of MBX-8025 in patients with homozygous familial hypercholesterolemia.

For additional information about CymaBay visit www.cymabay.com.

Contact Information